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Cardiovascular diseases (CVDs) are responsible for more 
than 16 million deaths worldwide, about 30% of total global 
deaths. Many of these deaths could be prevented by tackling 
major risk factors such as overweight and obesity as a result of 
unhealthy diet and physical inactivity, and smoking. Traditionally, 
CVDs have been considered a “Western” disease or a “disease of 
afﬂ  uence” and not a pressing public health concern for low-
income populations. However, within upper-middle-income and 
high-income countries, CVDs and their associated risk factors 
are increasingly concentrated among the lowest socioeconomic 
groups, and globally, 80% of all CVD deaths are in low-income 
and middle-income countries. 
In this month’s PLoS Medicine, Majid Ezzati and colleagues 
conclude that a large proportion of the world’s population 
living in low-income and middle-income countries should 
indeed be the focus of attention for CVD risk factors. This 
attention is needed because the aging populations of the 
currently low-income and middle-income countries are 
expected to be those among whom major cardiovascular risk 
factors will increasingly be concentrated.
The patterns of risks in relation to one another and to 
economic variables such as income are not fully established 
at the population level but need to be understood if better 
long-term policies and interventions are to be deployed. 
Ezzati and colleagues examined when interventions should 
be started by looking at the relationship between nutritional 
cardiovascular risk factors—overweight and obesity, and 
elevated blood pressure and cholesterol—and three economic 
indicators, using data for more than 100 countries. Their 
analysis uncovered economic–epidemiological patterns more 
complex than the “Western” or “afﬂ  uence” labels would suggest. 
They found that body mass index (BMI) and cholesterol 
increased rapidly in relation to national income, then ﬂ  attened, 
and eventually declined. BMI increased most rapidly until an 
income of about I$5,000 (international dollars) and peaked at 
about I$12,500 for women and I$17,000 for men. Cholesterol 
showed a similar pattern, but with some delay. The authors 
also found an inverse relationship between BMI/cholesterol 
and the share of household expenditure put towards food, 
and a positive relationship with proportion of population in 
urban centers, which may be due to changes in patterns of 
diet and physical activity with city life. For blood pressure and 
cholesterol, possible contributors to the decline at higher levels 
of income include dietary changes and use of pharmacological 
interventions.
As more interventions for blood pressure and cholesterol 
are adopted in high-income societies, the three risk factors will 
become a feature of low-income and middle-income nations, 
the authors say. Demographic and technological changes are 
increasingly modifying the income patterns of cardiovascular 
risk factors and shifting their burden to the developing world; 
as a result, low-income and middle-income countries will 
simultaneously face the burden of infectious disease and 
cardiovascular risk factors. Unless better interventions are 
pursued, we will face a world in which all major diseases are the 
diseases of the poor, the authors warn. (See also the Perspective 
by Thomas Novotny [DOI: 10.1371/journal.pmed.002010].)
Ezzati M, Vander Hoorn S, Lawes CMM, Leach R, James WPT, et 
al. (2005) Rethinking the “diseases of afﬂ  uence” paradigm: Global 
patterns of nutritional risks in relation to economic development. 
DOI: 10.1371/journal.pmed.0020133
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Coronary heart disease (CHD) is the 
leading cause of morbidity and mortality 
in developed countries, and identifying 
and treating patients with high 
cholesterol has an essential role in the 
prevention of CHD. Therapeutic lifestyle 
changes are important for general 
reduction of risk overall, but patients 
who are more likely to develop CHD, or 
who have high cholesterol, should be 
treated with statins. Statins inhibit HMG-
CoA reductase—a key enzyme in the 
cholesterol synthesis pathway.
Although we know that not all 
patients who may beneﬁ  t from statins 
receive treatment, there is limited 
information on how patients are 
treated according to their estimated 
risk of developing CHD. Patients may 
be classiﬁ  ed as at low, medium, or high 
risk of developing CHD according to the 
presence of CHD, some other medical 
conditions (for example, diabetes), and 
major risk factors including cholesterol 
level, smoking, lifestyle, and family 
history. Jun Ma and colleagues analyzed 
data from the National Ambulatory 
Medical Care Survey and the outpatient 
department component of the National 
Hospital Ambulatory Medical Care 
Survey to identify changes in treatment 
from 1993 to 2002, and to identify 
current clinical practice. These surveys 
have been validated against other data 
sources, and used in past research on 
cholesterol management.
Patterns of Statin Prescribing
DOI: 10.1371/journal.pmed.0020149
DOI: 10.1371/journal.pmed.0020148.g001
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There are at least 300 million acute cases of malaria each 
year globally, resulting in more than a million deaths. Ninety 
percent of deaths due to malaria occur in Africa south of the 
Sahara, and most occur in young children. Of the four types of 
human malaria—Plasmodium vivax, P. malariae, P. ovale, and P. 
falciparum—P. falciparum malaria is most common in Africa, 
and it accounts for most of the extremely high mortality south 
of the Sahara.
Malaria parasites are developing unacceptable levels of drug 
resistance, and many insecticides are no longer useful against 
mosquitoes transmitting the disease. Vaccine research has 
produced few hopeful candidates, and although millions of dollars 
are poured into research, an effective vaccine is years away.
One recurring theme in malaria vaccine research has been 
the high frequency of the gene for sickle cell hemoglobin 
(HbS) in malaria endemic regions, which is believed to be due 
to a heterozygote (HbAS) advantage against fatal malaria. The 
mechanism behind the high degree of resistance conferred by 
HbAS in severe and complicated malaria is still unknown, but 
recent observations have suggested the mechanism might 
involve an immune component.
In this month’s PLoS Medicine, Thomas Williams and colleagues 
reason that the best way to test whether malaria protection by 
HbAS has a signiﬁ  cant immune component is to see whether 
protection varies with age. They studied the age-speciﬁ  c malaria 
pattern in 1,054 children and adults living in Kiliﬁ   District on 
the coast of Kenya. They argued that if the malaria protection 
provided by HbAS were innate, it should be independent of 
malaria exposure and remain constant with age. However, if 
immune mechanisms were involved, protection should increase 
with age until children become functionally immune, when 
additional immunological advantage should be lost.
They found that overall HbAS was nearly 40% protective 
against mild clinical malaria.  Protection varied with age, 
increasing from 20% to 60% during the ﬁ  rst ten years of life, and 
thereafter returning to 30% in children more than ten years old.
The authors admit that this observation could be due to any 
factor that affects malaria risk and varies with age but state 
that accelerated immune acquisition seems the most likely 
explanation. They suggest several mechanisms for how HbAS 
could accelerate immune acquisition; for example, immunity could 
be mediated by accelerated acquisition of antibodies to altered 
host antigens expressed on the parasite-infected red cell surface.
In discussing their ﬁ  ndings the authors point out that their 
study focused on mild malaria. For accelerated malaria-speciﬁ  c 
immunity to be relevant to HbAS selection it would have to 
operate within a period of maximum risk for severe and fatal 
malaria. They note that in a recent study, conducted by another 
group in western Kenya, protection against severe malaria by 
HbAS was only seen in children 2–16 months old, but that in that 
study, no analysis was presented that addressed the effect of age 
within that range.
The authors conclude that the relevance of their current 
observations on mild clinical malaria to protection against severe 
and fatal malaria are unknown, and that further work must be 
done to better understand the role of HbAS in protection against 
malaria.
Williams TN, Mwangi TW, Roberts DJ, Alexander ND, Weatherall DJ, 
et al. (2005) An immune basis for malaria protection by the sickle cell 
trait. DOI: 10.1371/journal.pmed.0020128
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The researchers found that between 
1993 and 2002 the use of statins 
increased nearly 5-fold, from 9% to 49%, 
in ambulatory visits by patients with high 
cholesterol, but then declined to 36% in 
2002. Overall, the use of statins was three 
times more likely in 2001 and 2002 than 
in 1995 and 1996. Patients at high risk 
of CHD were more likely to use statins 
than other patients. However, among 
patients whose visit had a reported high 
cholesterol, only 50% of patient visits 
at high risk of CHD and 44% of those at 
moderate risk were prescribed statins in 
2002, well below the recommendations 
of current guidelines. Less than half the 
patient visits that arguably represent 
optimal opportunities for counseling 
services received counseling about how 
they might change their lifestyle. The 
study also showed inequities in use of 
statins for patients with different social 
and clinical characteristics, with lower 
usage in younger patients, females, 
African-Americans, and patients cared for 
by doctors who are not cardiologists.  
As the authors declare, the study 
was funded by a maker of one of the 
statins, but the information acquired 
is of general interest. Persistent gaps 
in statin therapy suggest a need for 
improved identiﬁ  cation of patients who 
may develop CHD, and treatment with 
statins when indicated, the authors say. A 
particular focus should be patients who 
are at risk of developing CHD. Education 
should be aimed at improving the practice 
of physicians—above all, those who 
are not heart specialists—so that they 
adhere to evidence-based medicine and 
published guidelines for cardiovascular 
risk reduction. In an accompanying 
Perspective (DOI: 10.1371/journal.
pmed.0020131), Fiona Turnbull from 
the George Institute for International 
Health says that physicians need to move 
away from making treatment decisions 
based on single risk factors and instead 
use an approach based on absolute risk. 
“An understanding of the concept of 
‘absolute risk’—the probability of a patient 
developing a cardiovascular event over a 
speciﬁ  ed time period—is crucial,” she says. 
Ma J, Sehgal NL, Ayanian JZ, Stafford RS 
(2005) National trends in statin use by 
coronary heart disease risk category. DOI: 
10.1371/journal.pmed.0020123PLoS Medicine  |  www.plosmedicine.org 0362
A link between high levels of homocysteine, a sulfur-
containing amino acid, and heart disease was ﬁ  rst suggested in 
the 1960s, when it became clear that patients with inborn errors 
of homocysteine metabolism were prone to develop severe 
cardiovascular disease in their teens and twenties. Treatment 
with homocysteine-lowering substances such as folate, vitamin 
B12, and betaine reduces the incidence of heart attacks and 
strokes in these patients. 
This led to the hypothesis that mildly elevated levels 
of homocysteine might contribute to vascular disease. 
Subsequently, several studies have found higher mean 
homocysteine levels in patients with coronary, peripheral, and 
cerebral vascular disease, particularly in those with vascular 
disease not readily explained by conventional risk factors such 
as high low-density lipoprotein (LDL) cholesterol, diabetes, or 
smoking. Several studies then sought to determine whether 
elevated homocysteine levels were a cause or effect of 
cardiovascular disease, and evidence for a causal relationship 
is accumulating. However, whether reduction in homocysteine 
levels translates into a reduction in heart disease is still an open 
question. 
“We are keenly awaiting the results from several ongoing 
trials. In the meantime, our group is trying to determine the 
risks and beneﬁ  ts associated with different homocysteine-
lowering nutrients,” said Margreet Olthof. She and her colleagues 
at the Wageningen Centre for Food Science analyzed four 
independent, placebo-controlled, randomized intervention 
studies that examined the effects of betaine, folic acid, and 
phosphatidylcholine on plasma homocysteine concentrations 
in healthy volunteers. They combined blood lipid data from 
the individual studies and compared changes in blood lipid 
concentrations between individuals taking homocysteine-
lowering nutrients and those taking placebo. 
They found that that betaine supplementation, while 
effective at lowering homocysteine, also increased LDL 
cholesterol and triacylglycerol. 
This raises the possibility that any potential beneﬁ  ts for 
cardiovascular health would be undermined by the adverse 
effects on blood lipids, and make betaine less suitable as 
a homocysteine-lowering agent in healthy individuals. 
The data on phosphatidylcholine were inconclusive, but 
supplementation of folic acid—the most common way to lower 
homocysteine levels—does not seem to affect blood lipids. 
The researchers conclude that folic acid “therefore remains 
the preferred treatment for lowering of blood homocysteine 
concentrations” in healthy individuals.
Olthof MR, van Vliet T, Verhoef P, Zock PL, Katan MB (2005) Effect 
of homocysteine-lowering nutrients on blood lipids: Results from 
four randomised, placebo-controlled studies in healthy humans. DOI: 
10.1371/journal.pmed.0020135
Comparison of Homocysteine-Lowering Drugs
DOI: 10.1371/journal.pmed.0020145
Schizophrenia is a devastating mental illness and a major 
contributor to the global burden of disease. In their quest to 
understand schizophrenia epidemiology, John McGrath and 
colleagues have previously undertaken a systematic review 
of schizophrenia incidence—that is, the number of new cases 
diagnosed each year in a speciﬁ  ed population (see BMC Medicine 2: 
e13). They now report results from a second systematic review that 
examines published studies on the prevalence of the disease—i.e., 
on the number of people who are suffering from the disease at a 
given time or within a speciﬁ  ed time interval. (Incidence studies 
can suggest risk factors that may underlie variations in the disease. 
Prevalence studies are central to health systems planning.)
Analyzing a total of 1,721 estimates from 188 studies and 
covering 46 countries, they calculated the following median 
prevalence estimates: 4.6 per 1,000 for point prevalence (deﬁ  ned 
as prevalence during any interval of less than a month), 3.3 for 
period prevalence (deﬁ  ned as prevalence during a period from 
1 to 12 months), 4.0 for lifetime prevalence (the proportion of 
individuals in the population who have ever manifested the 
disease and who are alive on a given day), and 7.2 for lifetime 
morbid risk (which attempts to include the entire lifetime of a 
birth cohort, both past and future, and includes those deceased 
at the time of the survey). 
These numbers are consistent with key policy documents 
about point prevalence, but suggest that the 0.5%–1% 
estimate for lifetime prevalence given in many textbooks is an 
overestimate. This estimate, the authors suggest, “is another 
example where the research community needs to review their 
belief systems in the face of data.” Another often quoted statistic, 
namely that “schizophrenia affects about one in a hundred” 
How Prevalent Is Schizophrenia?
DOI: 10.1371/journal.pmed.0020146
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This painting is frequently used to teach undergraduates what a 
person with schizophrenia experiences (Painting: Craig Finn)PLoS Medicine  |  www.plosmedicine.org 0363
most sensibly refers to lifetime morbid risk data. Here as well, 
the systematic analysis suggests that the reality is somewhat 
lower, and the authors suggest that “if we wish to provide the 
general public with a measure of the likelihood that individuals 
will develop schizophrenia during their lifetime, then a more 
accurate statement would be that about seven to eight 
individuals per 1,000 will be affected.”
The authors were surprised to ﬁ  nd no difference in prevalence 
between males and females, because their incidence review 
had found a male/female risk ratio of 1.4. On the other hand, the 
incidence study had revealed a higher incidence among migrant 
groups than among native-born individuals, and this was true 
for prevalence estimates as well. Compared to economically 
developed nations, the prevalence of schizophrenia is lower 
in developing nations, which is consistent with the literature 
showing that the course (i.e., prognosis) of schizophrenia is 
better in developing nations. 
Systematic reviews are secondary research, where the object 
of scrutiny is not the prevalence of schizophrenia per se but the 
literature on the topic, and the estimates in this review have to 
be treated accordingly. Regardless of exact numbers, however, 
the authors conclude that “many people with schizophrenia have 
persisting symptoms, despite the best mix of interventions we 
can offer.” It has been estimated that current interventions can at 
most reduce 25% of disease burden, thus the authors conclude 
that “this is a powerful argument for investing in applied and 
basic research.”
Saha S, Chant D, Welham J, McGrath J (2005) A systematic 
review of the prevalence of schizophrenia. DOI: 10.1371/journal.
pmed.0020141
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